Ventyx Biosciences Option Alert: Dec 19 $10 Calls at the Ask: 4201 vs 95 OI; Earnings 11/14 After Close [est] 

Ventyx Biosciences Option Alert: Dec 19 $10 Calls at the Ask: 4201 @ $1.4 vs 95 OI; Earnings 11/14 After Close [est] Ref=$8.36

Ventyx Biosciences

VENTYX BIOSCIENCES INC

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AIRE

AMZN

ARMP

BATL

BENF

BNBX

JWEL

QBTS

RBNE

SGBX

Brera Holdings PLC - Class B Ordinary Shares

SLMT

TSLA

VTYX

YDKG

Resumen de las acciones en alza y baja durante el premercado de EE. UU., con movimientos destacados en tecnología, energía y biotecnología.

Acciones de LendingClub suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

Ventyx Biosciences Inc

Press Releases

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Earnings

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Management

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Health Care

General

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Alumis

Alto Neuroscience

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Canopy Growth Corporation - Common Shares

Canopy Growth

Cormedix

Cronos Group

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

LB Pharmaceuticals

LENZ Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Zevra Therapeutics

Oppenheimer

Clear Street

Wells Fargo

Canaccord Genuity

Stifel

Comments

Ventyx Biosciences

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL